Navigation Links
Rise in Vulvar Precancers Leads to New Guidelines
Date:10/20/2011

THURSDAY, Oct. 20 (HealthDay News) -- The number of American women with precancerous cells of the vulva increased more than fourfold between 1973 and 2000, and the increase has led to the release Thursday of new treatment guidelines by two major medical groups.

Cancer of the vulva -- the outside of the genital area -- is usually caused by infection with human papillomavirus (HPV), which also causes cervical cancer. The precancerous condition -- known as vulvar intraepithelial neoplasia (VIN) -- should be treated with surgery, laser removal or medical therapy, according to the new guidelines from the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology.

VIN is divided into two main types. Usual-type VIN is often associated with cancer-causing strains of HPV and risk factors such as smoking and a weakened immune system. Differentiated VIN is often linked to dermatologic conditions of the vulva.

In most cases of VIN, which is increasingly evident among women in their 40s, there are visible raised lesions that may be white, gray, red, brown or black.

"Most women with VIN will not notice any symptoms, but some may have bleeding, discharge, or itching," Dr. Gerald F. Joseph, Jr., ACOG's vice president for practice activities, said in a college news release.

"It would be sensible for women to periodically examine their vulvar area for any unusual spots or lesions, and if they find something, make an appointment with their ob-gyn," he advised.

While VIN appears to be increasing in the United States, the risk of vulvar cancer is small when compared with cervical, ovarian and uterine cancers, Dr. L. Stewart Massad, a member of ACOG's Committee on Gynecologic Practice, said in the news release.

Much like precancerous cervical lesions, VIN is generally slow-growing, he said. "The quadrivalent HPV vaccine that helps prevent cervical cancer and genital warts has also been shown to decrease the risk of VIN," Massad noted.

Visual examination is the only way to diagnose VIN, and most lesions will need to be biopsied. If cancer is suspected, surgery is the preferred treatment. Laser removal is an acceptable treatment for VIN lesions that appear precancerous. Low-grade lesions can be monitored or treated with a topical cream (5 percent imiquimod) for 12 to 20 weeks, according to the guidelines.

The recurrence rate of VIN is high regardless of the treatment method, and women who've had VIN remain at risk for recurrent VIN and vulvar cancer for the remainder of their lives.

-- Robert Preidt

SOURCE: American College of Obstetricians and Gynecologists, news release, Oct. 20, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Chronic vulvar pain a reality for more than 100,000 women in southeast Michigan
2. Learning Lab of Brentwood Leads Free ADHD Seminar
3. Human Dental Technology Leads to Breakthroughs for Pet Dental Health at Sergeants Pet Care Products, Inc.
4. TechCFO Enters Mid-Atlantic Market; Rick Rolandi Leads DC Metro Office
5. Home Health Agency Owner Pleads Guilty in Connection with Detroit Fraud Scheme
6. New DNA technique leads to a breakthrough in child cancer research
7. AGA leads the way in GI innovation
8. Arsenic exposure activates an oncogenic signaling pathway; leads to increased cancer risk
9. KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs
10. China's Forbidden City Leads Landmark Climate Action for Earth Hour
11. McMaster researcher leads development of promising drug for inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rise in Vulvar Precancers Leads to New Guidelines  
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: